Healthcare Services

An Important Factor Driving the Leber Congenital Amaurosis Market Is the Rising Prevalence Of Inherited Retinal Diseases Driving The Growth Of The Market Due To Advancements In Genetic Testing And Diagnosis

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Leber Congenital Amaurosis Market Expected To Change Between 2026 And 2030?

The leber congenital amaurosis market has experienced robust expansion over recent years. Its projected growth trajectory indicates an increase from $1.06 billion in 2025 to $1.12 billion in 2026, advancing at a compound annual growth rate (CAGR) of 5.5%. Historically, this growth has been driven by factors such as limited therapeutic alternatives for inherited retinal disorders, heightened recognition of uncommon genetic eye conditions, improvements in retinal imaging techniques, the expansion of pediatric ophthalmology services, and nascent research efforts in gene replacement therapy.

The market for Leber Congenital Amaurosis is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.5%. This growth during the forecast period is primarily driven by increased investments in ophthalmic gene therapy research, the expansion of precision medicine programs, a rising number of regulatory clearances for therapies targeting rare diseases, broader acceptance of sophisticated genetic testing, and enhanced healthcare accessibility for rare genetic conditions. Key trends expected during this period involve a wider range of gene therapy approvals for inherited retinal diseases, a heightened emphasis on early genetic screening and diagnosis, an increase in clinical trials for innovative retinal regeneration treatments, greater uptake of assistive vision technologies, and progress in retinal prosthesis and bionic eye solutions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22033&type=smp

Which Major Factors Are Driving The Expansion Of The Leber Congenital Amaurosis Market?

The market for Leber congenital amaurosis (LCA) is expected to grow due to the increasing occurrence of inherited retinal diseases. Inherited retinal diseases (IRDs) are defined as genetic conditions that impact the retina, the light-sensitive tissue at the rear of the eye essential for sight. This rise in inherited retinal diseases is attributed to advancements in genetic testing, improved awareness and diagnostic methods, and an extended life expectancy. Progress in genetic testing has simplified the diagnosis of inherited retinal diseases, leading to the identification of more cases. Leber congenital amaurosis aids in advancing the understanding of inherited retinal diseases by revealing genetic mutations and disease mechanisms that contribute to the development of targeted therapies and treatments. For example, in January 2025, data from the UK Parliament’s House of Commons Library, a UK-based government administration, indicated that approximately 25,000 people in the UK were affected by inherited retinal diseases in 2024, an annual increase of 2%. Consequently, the growing prevalence of inherited retinal diseases acts as a primary driver for the Leber congenital amaurosis market.

How Is The Leber Congenital Amaurosis Market Structured Across Different Segments?

The leber congenital amaurosis market covered in this report is segmented –

1) By Treatment Type: Gene Therapy, Pharmaceutical Drugs, Retinal Prosthesis, Assistive Devices, Other Treatments

2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth), Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years), Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)

3) By Distribution Channel: Direct Tender, Retail Sales

4) By End User: Hospitals, Specialized Eye Clinics, Ophthalmology Research Centers, Home Care Settings, Other End Users

Subsegments:

1) By Gene Therapy: RPE65 Gene Replacement Therapy, CRISPR-Based Gene Editing, AAV (Adeno-Associated Virus) Vector Therapy, Emerging Experimental Gene Therapies

2) By Pharmaceutical Drugs: Retinoid-Based Therapies, Neuroprotective Agents, Anti-Inflammatory Drugs, Antioxidant Therapies

3) By Retinal Prosthesis: Implantable Retinal Chips, Artificial Retinal Stimulation Devices, Bionic Eye Technology

4) By Assistive Devices: Low Vision Aids, Screen Readers and Braille Devices, Mobility Aids for Vision Impairment

5) By Other Treatments: Stem Cell Therapy, Optogenetics-Based Treatments, Visual Rehabilitation Programs, Nutritional and Dietary Interventions

What Trends Are Advancing Progress In The Leber Congenital Amaurosis Market?

Leading companies in the leber congenital amaurosis market are concentrating on developing innovative solutions, such as RNA-based treatments, to enhance vision restoration and disease management. RNA-based treatments utilize RNA molecules to address diseases by targeting genetic processes, including mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Théa S.A.S., a France-based pharmaceutical company, established Sepul Bio, a specialized business unit dedicated to advancing RNA therapies for inherited retinal diseases, with a specific focus on sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. After the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is well-prepared to achieve substantial progress in addressing these rare genetic disorders.

Which Major Players Dominate The Leber Congenital Amaurosis Market?

Major companies operating in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OÜ, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., Ophthotech Corporation, Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

Read the full leber congenital amaurosis market report here:

https://www.thebusinessresearchcompany.com/report/leber-congenital-amaurosis-global-market-report

Which Region Currently Holds The Largest Share Of The Leber Congenital Amaurosis Market?

North America was the largest region in the leber congenital amaurosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leber congenital amaurosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leber Congenital Amaurosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22033&type=smp

Browse Through More Reports Similar to the Global Leber Congenital Amaurosis Market 2026, By The Business Research Company

Congenital Heart Disease Chd Global Market Report

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Gauchers Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795